16 results for "Jessica Menis"
Showing 1–16 · 1.65 seconds · RSS
-
Journal Article
New clinical research strategies in thoracic oncology: clinical trial design, adaptive, basket and umbrella trials, new end-points and new evaluations of response
In the genomics era, our main goal should be to identify large and meaningful differences in small, molecularly selected groups of patients. Classical phase I, II and III models for drug development require large resources, limiting the number of experimental agents that can be tested and making…
-
Journal Article
Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio
IntroductionBone metastases (BMs) are a negative prognostic factor in patients with non-small cell lung cancer (NSCLC). Although immune-checkpoint inhibitors (ICIs) have dramatically changed the therapeutic landscape of NSCLC, little information is available on BMs from NSCLC treated with ICIs…
-
Journal Article
Fulminating septic shock from Clostridium perfringens in an early breast cancer patient with severe myalgia after docetaxel treatment
Anaerobic bacteraemia could be a lifethreatening condition in neutropenic patients receiving chemotherapy. Taxane therapy is associated with necrotising inflammation of the caecum (named also typhlitis) that could be a potential source for bacteraemia. We report the case of a sudden onset of septic…
-
Journal Article
Combined Immunoscore for Prognostic Stratification of Early Stage Non-Small-Cell Lung Cancer
BackgroundTo date, no combined immunoscore has been evaluated for prognostic stratification of early stage non-small-cell lung cancer (NSCLC). The main goal of this study was to investigate the prognostic impact of programmed death ligand 1 (PD-L1) expression and different immune cell components…
-
Journal Article
Implementation outcomes of early nutritional screening and referral for patients with thoracic cancers
Summary: Background & Aims: Nutritional impairments may negatively impact different outcomes, including survival, in patients with thoracic malignancies. Despite this, a low number of patients are screened for nutritional risk and referred to an appropriate service. The aim of this study is to…
-
Journal Article
SCLC Treatment in the Immuno-Oncology Era: Current Evidence and Unmet Needs
Small cell lung cancer (SCLC) represents about 13%–15% of all lung cancers. It has a particularly unfavorable prognosis and in about 70% of cases occurs in the advanced stage (extended disease). Three phase III studies tested the combination of immunotherapy (atezolizumab, durvalumab with or…
-
Journal Article
Impact of the Oncologist's Recommendation on Exercise Levels and Quality of Life in Patients With Lung Cancer: The ORE Randomized Controlled Trial
ABSTRACT Background Although physical activity is associated with improved survival in lung cancer, most patients remain inactive. This study examined the impact of an oncologist's recommendation on exercise quantity, sedentary behavior, and quality of life (QoL) in patients with lung cancer…
-
Journal Article
How the COVID-19 Pandemic Impacted on Integrated Care Pathways for Lung Cancer: The Parallel Experience of a COVID-Spared and a COVID-Dedicated Center
IntroductionThe COVID-19 pandemic has proved to be a historic challenge for healthcare systems, particularly with regard to cancer patients. So far, very limited data have been presented on the impact on integrated care pathways (ICPs).MethodsWe reviewed the ICPs of lung cancer patients who…
-
Journal Article Full text
Anticipating EGFR Targeting in Early Stages of Lung Cancer: Leave No Stone Unturned
Background: The current treatment landscape of early stage lung cancer is rapidly evolving, particularly in EGFR mutant non-small cell lung cancer (NSCLC), where target therapy is moving to early stages. In the current review, we collected the available data exploring the impact of EGFR targeting…
-
Journal Article
Body composition derangements in lung cancer patients treated with first‐line pembrolizumab: A multicentre observational study
Abstract Background While immune checkpoint inhibitors (ICIs) are increasingly reshaping the therapeutic landscape of non‐small‐cell lung cancer (NSCLC), only a limited proportion of patients achieve a relevant and long‐lasting benefit with these treatments, calling for the identification of…
-
Journal Article
Prognostic and predictive implications of tumor suppressor gene alterations in non-small cell lung cancer
Abstract In addition to identifying alterations suitable for molecularly targeted therapy (TT), comprehensive genomic profiling (CGP) may convey prognostic/predictive information in advanced non-small-cell lung cancer (aNSCLC). We investigated the impact of tumor suppressor gene alterations (TSGAs)…
-
Journal Article
Tissue- and liquid-biopsy based NGS profiling in advanced non-small-cell lung cancer in a real-world setting: the IMMINENT study
IntroductionTo date, for all non-small cell lung cancer (NSCLC) cases, it is recommended to test for driver alterations to identify actionable therapeutic targets. In this light, comprehensive genomic profiling (CGP) with next generation sequencing (NGS) has progressively gained increasing…